Streetbeat News

DRUG

Bright Minds Biosciences Inc.

https://brightmindsbio.com

Industry

Biotechnology

Bright Minds Biosciences Inc., a pre-clinical biosciences company, develops 5-HT (serotonin) medicines to improve the lives of patients with severe and life-altering diseases. Its portfolio of selective 5-HT receptor agonists comprises 5-HT2C, 5-HT2A, and 5-HT2C/A for the treatment of epilepsy, pain, and neuropsychiatry. The company has collaboration with National Institutes of Health for the treatment of epilepsy; University of Texas Medical Branch to treat impulse control disorders, such as binge eating; and Medical College of Wisconsin. The company was incorporated in 2019 and is headquartered in Vancouver, Canada.

Open

42.00

Mkt cap

241M

Volume

108K

High

43.29

P/E Ratio

-62.87

52-wk high

79.02

Low

39.59

Div yield

N/A

52-wk low

0.93

Bright Minds Biosciences Inc. (NASDAQ:DRUG) shares surged over 100% on Friday following the announcement of a $35 million non-brokered private placement. The funds will be used for working capital and R&D. The stock is trading at a significantly higher volume than usual.

Portfolio Pulse from Dylan Berman

October 18, 2024 | 3:11 pm

Bright Minds Biosciences shares have resumed trading, which may impact investor sentiment and stock price movements.

Portfolio Pulse from Benzinga Newsdesk

October 18, 2024 | 3:00 pm

Bright Minds Biosciences experienced a significant stock price surge, with shares initially resuming trade and then being halted due to a circuit breaker as the stock rose by 186.2%.

Portfolio Pulse from Benzinga Newsdesk

October 18, 2024 | 2:56 pm

Bright Minds Biosciences shares were halted due to a circuit breaker as the stock surged 166%.

Portfolio Pulse from Benzinga Newsdesk

October 18, 2024 | 2:42 pm

U.S. stocks showed mixed performance with the Dow Jones falling over 100 points, while the NASDAQ and S&P 500 rose. Netflix reported strong Q3 results, surpassing revenue expectations and increasing its subscriber base. Several stocks experienced significant price movements, including Catheter Precision, Bright Minds Biosciences, and SOBR Safe, which saw substantial gains, while NKGen Biotech, Orgenesis, and NuZee faced declines.

Portfolio Pulse from Avi Kapoor

October 18, 2024 | 2:27 pm

On October 18th, SOBR Safe, Bright Minds Biosciences, and Intuitive Surgical experienced significant stock movements. SOBR Safe surged 272% after withdrawing a public offering. Bright Minds Biosciences rose 73% due to a $35 million private placement. Intuitive Surgical increased 9% following strong Q3 results.

Portfolio Pulse from Benzinga Newsdesk

October 18, 2024 | 12:57 pm

Bright Minds Biosciences shares rose following the announcement of a $35 million non-brokered private placement.

Portfolio Pulse from Benzinga Newsdesk

October 18, 2024 | 12:09 pm

Bright Minds Biosciences has announced a $35 million private placement of common shares and pre-funded warrants at $21.70 per share. The pre-funded warrants are exercisable at $0.001 per share for up to five years.

Portfolio Pulse from Benzinga Newsdesk

October 18, 2024 | 12:03 pm

Firefly Neuroscience and Bright Minds Biosciences have successfully completed a Phase 1 study of BMB-101, a compound for neuropsychiatric disorders, using AI-driven data analysis. The study showed positive results, and BMB-101 will advance to Phase 2 trials.

Portfolio Pulse from Juan Spínelli

October 17, 2024 | 2:55 pm

Perceptive Advisors LLC, Joseph Edelman, and Perceptive Life Sciences Master Fund have filed a Schedule 13G with the SEC, indicating a 9.6% passive stake in Bright Minds Biosciences, consisting of 430,000 common shares as of October 14, 2024.

Portfolio Pulse from Benzinga Newsdesk

October 16, 2024 | 5:16 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.